粪便免疫化学检测血红蛋白:分析挑战与潜在解决方案
定量粪便免疫化学检测血红蛋白(FIT)日益用于结直肠癌筛查及下消化道症状患者的分诊。国际临床化学联合会FIT工作组概述了主要分析前变量、外部质量评估方案、第三方内部质控材料获取及方法标准化/一致化等分析挑战,并提出相应解决思路。
要点
- FIT临床应用价值明确,但分析前变异是主要挑战之一。
- FIT外部质量评估方案建立困难,第三方内部质控材料获取受限。
- FIT方法缺乏标准化或一致化,需推动方法学统一。
核心结论
- FIT临床应用价值已充分报道,但分析前变异、外部质量评估困难、第三方内部质控材料获取受限及方法缺乏标准化/一致化是主要分析挑战。
研究设计与样本
- 国际临床化学联合会FIT工作组针对FIT分析挑战开展工作总结,概述分析前变量、外部质量保证方法、第三方内部质量保证材料解决方案及标准化/一致化挑战。
主要发现
- FIT分析挑战包括分析前变异、外部质量评估方案建立困难、第三方内部质控材料获取受限以及FIT方法缺乏标准化或一致化。
临床怎么用
- 临床使用定量FIT时需关注分析前变异对结果的影响,并重视方法标准化/一致化及质量保证体系的建立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Quantitative faecal immunochemical tests for haemoglobin (FIT) are being used increasingly around the world in colorectal cancer screening programmes, and in patients presenting with lower bowel symptoms to determine who should proceed to further bowel visualisation investigations, usually colonoscopy. The clinical utility of FIT is well reported. There are a number of analytical challenges including pre-analytical variation, difficulty setting up external quality assessment schemes, access to third party internal quality control material and a lack of standardisation or harmonisation of FIT methods. Here we report the work of the International Federation of Clinical Chemistry FIT Working Group. We provide an overview of the main pre-analytical variables; discuss different approaches to external quality assurance of FIT; propose a solution to third party internal quality assurance materials and summarise the challenges of standardisation and harmonisation of FIT.
引用
- Benton SC, Symonds E, Djedovic N, et al. Faecal immunochemical tests for haemoglobin: Analytical challenges and potential solutions. Clin Chim Acta. 2021. PMID: 33571484. doi:10.1016/j.cca.2021.01.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。